A First-In-Human study of HS-10383, a Selective P2X3 Receptor Antagonist for the treatment of Refractory or Unexplained Chronic Cough, in Healthy Chinese Subjects

被引：0
|
作者：
Li, Qian [1 ,2 ]
Chen, Ke-Guang [1 ,2 ]
Zhang, Ye-Hui [1 ,2 ]
Zhou, Hai-Yan [1 ,2 ]
Ye, Pan-Pan [1 ,2 ]
Song, Lin-Lin [1 ,2 ]
Zhao, Fu-Rong [1 ,2 ]
Shi, Jin-Yi [1 ,2 ]
Wu, Qiong [3 ]
Yu, Xiang-Qing [3 ]
Pan, Chao [3 ]
Yuan, Dong [3 ]
Xu, Miao [3 ]
Xing, Aiping [3 ]
Yang, Xin-Mei [1 ,2 ]
Zhao, Wei [1 ,2 ,4 ]
机构：
[1] Shandong First Med Univ, Dept Clin Pharm, Affiliated Hosp 1, Jinan, Peoples R China
[2] Shandong Prov Qianfoshan Hosp, Shandong Engn & Technol Res Ctr Pediat Drug Dev, Shandong Med & Hlth Key Lab Clin Pharm, Jinan, Peoples R China
[3] Jiangsu Hansoh Pharmaceut Grp Co Ltd, Dept Clin Pharm, Lianyungang, Peoples R China
[4] Shandong Univ, Sch Pharmaceut Sci, Minist Educ,Dept Clin Pharm, Key Lab Chem Biol,Cheeloo Coll Med, Jinan, Peoples R China
来源：
RESPIROLOGY | 2023年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO13-6
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [41] Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant
    Klaus Francke
    Niladri Chattopadhyay
    Stefan Klein
    Antje Rottmann
    Dennis Krickau
    Jeroen van de Wetering
    Christian Friedrich
    European Journal of Drug Metabolism and Pharmacokinetics, 2023, 48 : 75 - 87
  • [42] Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant
    Francke, Klaus
    Chattopadhyay, Niladri
    Klein, Stefan
    Rottmann, Antje
    Krickau, Dennis
    van de Wetering, Jeroen
    Friedrich, Christian
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2023, 48 (01) : 75 - 87
  • [43] Improvements in cough severity and cough-related quality of life in a phase 2 trial (RELIEF) with the P2X3 antagonist BLU-5937 in refractory chronic cough (RCC)
    Birring, Surinder S.
    Smith, Jaclyn A.
    Morice, Alyn H.
    Sher, Mandel
    Hull, James H.
    Goldsobel, Alan B.
    Lanouette, Sylvain
    Li, Ella
    Harvey, Laurent
    Bonuccelli, Catherine M.
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [44] P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough
    Cui, Wen-Wen
    Wang, Si-Yu
    Zhang, Yu-Qing
    Wang, Yao
    Fan, Ying-Zhe
    Guo, Chang-Run
    Li, Xing-Hua
    Lei, Yun-Tao
    Wang, Wen-Hui
    Yang, Xiao-Na
    Hattori, Motoyuki
    Li, Chang-Zhu
    Wang, Jin
    Yu, Ye
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2022, 20 : 1642 - 1653
  • [45] Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough
    Gupta, Pranav
    Hussain, Azher
    Ford, Anthony P.
    Smith, Steven
    Nussbaum, Jesse C.
    Stoch, Aubrey
    Iwamoto, Marian
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (09): : 1054 - 1067
  • [46] Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study
    Christian Friedrich
    Klaus Francke
    Isabella Gashaw
    Christian Scheerans
    Stefan Klein
    Lueder Fels
    Jaclyn A. Smith
    Thomas Hummel
    Alyn Morice
    Clinical Pharmacokinetics, 2022, 61 : 1143 - 1156
  • [47] Safety and pharmacokinetics of BAY 1817080, a P2X3 receptor antagonist, in healthy subjects: Results from a double-blind, randomised study
    Friedrich, Christian
    Francke, Klaus
    Gashaw, Isabella
    Scheerans, Christian
    Klein, Stefan
    Fels, Lueder
    Smith, Jaclyn
    Hummel, Thomas
    Morice, Alyn
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (03) : 1614 - 1616
  • [48] Mk-7264, A P2x3 Receptor Antagonist, Reduces Cough Frequency In Patients With Refractory Chronic Cough: Results From A Randomized, Controlled, Phase 2b Clinical Trial
    Smith, J. A.
    Kitt, M. M.
    Morice, A. H.
    Birring, S. S.
    McGarvey, L. P.
    Sher, M. R.
    Ford, A. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [49] Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study
    Friedrich, Christian
    Francke, Klaus
    Gashaw, Isabella
    Scheerans, Christian
    Klein, Stefan
    Fels, Lueder
    Smith, Jaclyn A.
    Hummel, Thomas
    Morice, Alyn
    CLINICAL PHARMACOKINETICS, 2022, 61 (08) : 1143 - 1156
  • [50] PRIOR SPECIALIST CONSULTATIONS AND TREATMENTS IN A REFRACTORY CHRONIC COUGH POPULATION ENROLLED IN A PHASE 2B STUDY OF THE P2X3 ANTAGONIST BLU-5937
    Dicpinigaitis, Peter V.
    Mcgarvey, Lorcan
    Smith, Jaclyn A.
    Blaiss, Michael
    Iyer, Vivek N.
    Lanouette, Sylvain
    Yang, Ronghua
    Garin, Margaret
    Bonuccelli, Catherine M.
    CHEST, 2022, 162 (04) : 2487A - 2488A
12345